Kinetic Concepts

Orthofix Announces Changes to Board of Directors

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Surgery, Medical Devices, Other Health, Health, Lead, Executive, Senior, Audit, Kodak, Burris, Sale, Accounting, Retirement, Ethics, CFO, Johnson & Johnson, Applied Biosystems, Kinetic Concepts, Management

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik has been re-appointed as the Chair of the Company’s Board of Directors.

Key Points: 
  • Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik has been re-appointed as the Chair of the Company’s Board of Directors.
  • Additionally, shareholders re-elected Wayne Burris who previously served on the Orthofix board from 2021-2022.
  • As previously announced Jon Serbousek, who served as Executive Chairman of the Board, did not stand for re-election at the annual shareholders meeting held yesterday.
  • Burzik previously served as the Company’s Chair of the Board from 2021-2022 before assuming the position of Lead Independent Director of the new combined board that was formed following the merger of SeaSpine and Orthofix.

Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive Officer

Retrieved on: 
Thursday, March 23, 2023
Insulin, Neurovascular bundle, Type 2 diabetes, Butterfly network, Duodenum, Medtronic, Type 2, Blood, Patient, Kinetic Concepts, FDA, Safety, Disease, Pharmaceutical industry, Covidien

MINNEAPOLIS, March 23, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Stacey Pugh as Chief Executive Officer (CEO). In this role Stacey will lead the organization as it expands its clinical initiatives evaluating the novel ReCET™ Procedure for the treatment of Type 2 Diabetes.

Key Points: 
  • MINNEAPOLIS, March 23, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Stacey Pugh as Chief Executive Officer (CEO).
  • "We are thrilled to have Stacey join the Endogenex team," said James Eadie MD, Endogenex Board Member and Managing Director, Santé.
  • "Stacy is a proven leader with extensive experience in running global clinical and commercial stage medical device organizations.
  • She spent the first half of her medical device career leading clinical and medical affairs teams at Medtronic, Covidien, and Kinetic Concepts.

MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer

Retrieved on: 
Tuesday, January 3, 2023
Newton, Good tissue practice, Medtech, Kinetic Concepts, Good manufacturing practice, Texas A&M University, Industrial engineering, Johnson & Johnson, Patient, Lifecell, Government, CGMP-specific phosphodiesterase type 5, Tissue, Catalent, NYU, Stem cell, Pharmaceutical industry, Management

MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain, procurement, quality, and regulatory functions. Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services.

Key Points: 
  • MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain, procurement, quality, and regulatory functions.
  • Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services.
  • “We are happy to begin 2023 with the addition of Ricci Whitlow to the MIMEDX leadership team,” stated Todd Newton, MIMEDX interim Chief Executive Officer.
  • We believe Ricci is this leader.”
    “I am excited to be joining the MIMEDX team during this important period in the Company’s history,” stated Ms. Whitlow.

BioBridge Global announces appointment of John Youngdahl as Chief Financial Officer

Retrieved on: 
Wednesday, July 6, 2022
Blood, CEO, Kinetic Concepts, Â, Senior, Texas State University, BioBridge Global, Information services, GLOBE, Plasma, MBA, BBG, Retirement, Regenerative medicine, Gustavus Adolphus College, Finance, Family, Getinge Group, Leadership, Dell, Management

San Antonio, Texas, July 06, 2022 (GLOBE NEWSWIRE) -- BioBridge Global, a San Antonio-based nonprofit healthcare services enterprise, integrating donor-to-patient services to enable the future of biotherapeutic solutions, announced today that it has named John Youngdahl MBA as Senior Vice President and Chief Financial Officer, effective immediately.

Key Points: 
  • San Antonio, Texas, July 06, 2022 (GLOBE NEWSWIRE) -- BioBridge Global, a San Antonio-based nonprofit healthcare services enterprise, integrating donor-to-patient services to enable the future of biotherapeutic solutions, announced today that it has named John Youngdahl MBA as Senior Vice President and Chief Financial Officer, effective immediately.
  • Youngdahl has been with the enterprise since December 2016, serving as Executive Director of Financial Planning and Analysis.
  • He succeeds Glenn Kues CPA, who has served as Senior Vice President and Chief Financial Officer since December 2017.
  • Youngdahl held senior financial positions in Arjo-Huntleigh Getinge AB, Kinetic Concepts Inc. (now 3M/KCI) and Dell Financial Services.

NanoVibronix Expands Board of Directors with Appointment of Two New Independent Directors

Retrieved on: 
Thursday, January 13, 2022
Medical Devices, Health, Aurora, Sentinel, Biofilm, Research, Rori, SEC, SAW, Financial compensation, NASDAQ, Committee, Kinetic Concepts, U.S. Securities and Exchange Commission, JD, Industry, Moses Austin, Gas, CST Brands, Certified Public Accountant, LLC, Compliance, Treasurer, Risk, Clinical trial, COVID-19, Professional Football Compensation Committee, XV, KLRN, Executive, Nasdaq, Company, Financial Stability and Development Committee, KCI, Ernst & Young, Forward-looking statement, Patient, AV, Audit committee, Advisory board, Leadership, Jenkins, Technology, Medtech, Commerce, The Advisory Board Company, Gilchrist, KIND, Martindale-Hubbell, Deloitte, Sale, Trademark dilution, Ernst, Jerusalem College of Technology, Security (finance), University, Board, Medical imaging, Management, Risk management, New York University

Following the appointments, the board of NanoVibronix will be comprised of eight directors, six of whom are considered independent as defined under the Nasdaq Listing Rules.

Key Points: 
  • Following the appointments, the board of NanoVibronix will be comprised of eight directors, six of whom are considered independent as defined under the Nasdaq Listing Rules.
  • In addition to her management responsibilities, Rori has a sophisticated practice focusing on business litigation and corporate governance issues.
  • Previously, she served as Chair of the Advisory Board of ReferWell, f/k/a Urgent Consult, LLC, a start-up in the health tech business.
  • She also serves on the Board of Directors of Kids in Need of Defense (KIND), a not-for-profit organization where she served on its Compensation Committee.

Xenex Expands Board of Directors with Addition of Accounting Industry Leader Aaron deSouza

Retrieved on: 
Monday, November 1, 2021
Medical Devices, Health, Technology, Infectious Diseases, Hospitals, Other Technology, Grant Thornton International, Accounting, Prison, IPO, University, Hospital, Deloitte, Private equity, Virus, Abbott Laboratories, Frost & Sullivan, Double-barrelled name, Severe acute respiratory syndrome coronavirus 2, Airport, Hospice, Infection, PLC, LLC, CEO, COVID-19, Battery Ventures, Bacteria, Growth, Solution, Brook Andrew, MIT, School, Kinetic Concepts, Management, Vaccine

Xenex Disinfection Services , a world leader in UV disinfection technology for healthcare facilities, today announced Aaron deSouza has joined its board of directors.

Key Points: 
  • Xenex Disinfection Services , a world leader in UV disinfection technology for healthcare facilities, today announced Aaron deSouza has joined its board of directors.
  • He is working closely with Xenexs leadership team and other board members to support Xenexs strategic growth initiatives.
  • DeSouza has significant experience supporting boards of directors and audit committees with strategy, finance, risk mitigation, internal controls, regulatory filings and IPO (initial public offering) matters.
  • He also worked for Deloitte LLP where he advised on audit, accounting, and U.S. and international mergers and acquisitions.

$4.5 Billion Negative Pressure Wound Therapy Devices (Conventional, Single-Use, Accessories) Markets - Global Industry Analysis and Growth Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 25, 2020
Surgery, Health, Medical devices, Medicine, Clinical medicine, Branches of biology, Medical equipment, Necrosis, Negative pressure, Pressure ulcer, Negative-pressure wound therapy, Wound, Kinetic Concepts

The "Negative Pressure Wound Therapy Devices Market Research Report: By Product (Conventional, Single-Use, Accessories), Wound Type (Chronic, Acute), End User (Hospitals, Home-Care Settings) - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Negative Pressure Wound Therapy Devices Market Research Report: By Product (Conventional, Single-Use, Accessories), Wound Type (Chronic, Acute), End User (Hospitals, Home-Care Settings) - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global negative pressure wound therapy (NPWT) devices market was valued at $2,178.4 million in 2019 and is expected to reach to $4,541.5 million by 2030, at a 7.3% CAGR between 2020 and 2030
    The negative pressure wound therapy devices market is witnessing a slowdown during the COVID-19 scenario, as the badly hit supply chains have resulted in the low manufacturing and trade of NPWT products.
  • North America has been the highest revenue contributor to the negative pressure wound therapy devices market till now.
  • The negative pressure wound therapy devices market is predicted to witness the most rapid advance in the APAC region in the years to come.

Negative Pressure Wound Therapy Devices Market to Reach $4,541.5 Million by 2030: P&S Intelligence

Retrieved on: 
Thursday, September 24, 2020
Medicine, Clinical medicine, Branches of biology, Medical equipment, Necrosis, Negative pressure, Negative-pressure wound therapy, Pressure ulcer, Wound, Kinetic Concepts

This is expected to be significant in driving the global negative pressure wound therapy (NPWT) devices market from $2,178.4 million in 2019 to $4,541.5 million by 2030, at a 7.3% CAGR between 2020 and 2030, according to P&S Intelligence.

Key Points: 
  • This is expected to be significant in driving the global negative pressure wound therapy (NPWT) devices market from $2,178.4 million in 2019 to $4,541.5 million by 2030, at a 7.3% CAGR between 2020 and 2030, according to P&S Intelligence.
  • The negative pressure wound therapy devices market is witnessing a slowdown during the COVID-19 scenario, as the badly hit supply chains have resulted in the low manufacturing and trade of NPWT products.
  • North America has been the highest revenue contributor to the negative pressure wound therapy devices market till now.
  • Browse report with in-depth COVID-19 impact analysis on Negative Pressure Wound Therapy Devices Market Research Report: By Product (Conventional, Single-Use, Accessories), Wound Type (Chronic, Acute), End User (Hospitals, Home-Care Settings) - Global Industry Analysis and Growth Forecast to 2030 @ https://www.psmarketresearch.com/market-analysis/negative-pressure-wound...
    The negative pressure wound therapy devices market is predicted to witness the most rapid advance in the APAC region in the years to come.

Negative Pressure Wound Therapy Devices Market to Reach $4,541.5 Million by 2030: P&S Intelligence

Retrieved on: 
Thursday, September 24, 2020
Medicine, Clinical medicine, Branches of biology, Medical equipment, Necrosis, Negative pressure, Negative-pressure wound therapy, Pressure ulcer, Wound, Kinetic Concepts

This is expected to be significant in driving the global negative pressure wound therapy (NPWT) devices market from $2,178.4 million in 2019 to $4,541.5 million by 2030, at a 7.3% CAGR between 2020 and 2030, according to P&S Intelligence.

Key Points: 
  • This is expected to be significant in driving the global negative pressure wound therapy (NPWT) devices market from $2,178.4 million in 2019 to $4,541.5 million by 2030, at a 7.3% CAGR between 2020 and 2030, according to P&S Intelligence.
  • The negative pressure wound therapy devices market is witnessing a slowdown during the COVID-19 scenario, as the badly hit supply chains have resulted in the low manufacturing and trade of NPWT products.
  • North America has been the highest revenue contributor to the negative pressure wound therapy devices market till now.
  • Browse report with in-depth COVID-19 impact analysis on Negative Pressure Wound Therapy Devices Market Research Report: By Product (Conventional, Single-Use, Accessories), Wound Type (Chronic, Acute), End User (Hospitals, Home-Care Settings) - Global Industry Analysis and Growth Forecast to 2030 @ https://www.psmarketresearch.com/market-analysis/negative-pressure-wound...
    The negative pressure wound therapy devices market is predicted to witness the most rapid advance in the APAC region in the years to come.

The Global Therapeutic Bed Market is expected to grow from USD 1,423.13 Million in 2018 to USD 1,856.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 3.86%

Retrieved on: 
Thursday, April 16, 2020
Bazaars, Marketplace, Kinetic Concepts

On the basis of Product, the Global Therapeutic Bed Market is studied across Accessories, Clinical Beds, and Household Beds.

Key Points: 
  • On the basis of Product, the Global Therapeutic Bed Market is studied across Accessories, Clinical Beds, and Household Beds.
  • On the basis of Type, the Global Therapeutic Bed Market is studied across Acute Care, Critical Care, and Long-Term.
  • What are the factors that affect the growth in the Global Therapeutic Bed Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Therapeutic Bed Market?